WO2001042248A1 - Verfahren zur herstellung von thienopyrimidinen - Google Patents
Verfahren zur herstellung von thienopyrimidinen Download PDFInfo
- Publication number
- WO2001042248A1 WO2001042248A1 PCT/EP2000/012351 EP0012351W WO0142248A1 WO 2001042248 A1 WO2001042248 A1 WO 2001042248A1 EP 0012351 W EP0012351 W EP 0012351W WO 0142248 A1 WO0142248 A1 WO 0142248A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- formula
- solvent
- carbon atoms
- reaction
- Prior art date
Links
- 0 *Sc1c(CO)cccc1 Chemical compound *Sc1c(CO)cccc1 0.000 description 1
- DJMPKBCKCBPVQM-UHFFFAOYSA-N Cc1nc(Cl)c(c2ccccc2[s]2)c2n1 Chemical compound Cc1nc(Cl)c(c2ccccc2[s]2)c2n1 DJMPKBCKCBPVQM-UHFFFAOYSA-N 0.000 description 1
- NBOMNTLFRHMDEZ-UHFFFAOYSA-N OC(c1ccccc1S)=O Chemical compound OC(c1ccccc1S)=O NBOMNTLFRHMDEZ-UHFFFAOYSA-N 0.000 description 1
- FYWFCRHZXORPFH-UHFFFAOYSA-N OCc1ccccc1S Chemical compound OCc1ccccc1S FYWFCRHZXORPFH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Definitions
- the invention relates to a process for the preparation of compounds of the formula I.
- A stands for an alkyl group with 1 to 6 carbon atoms.
- Drugs that contain the heterocycle system of compounds of formula I are described for example in DE-198 190 23 AI. These compounds and their salts are well tolerated and have very valuable pharmacological properties. In particular, they show a specific inhibition of cGMP phosphodiesterase (PDE V).
- PDE V cGMP phosphodiesterase
- the compounds are therefore suitable for the treatment of diseases of the cardiovascular system, in particular heart failure and for the treatment and / or therapy of erectile dysfunction (ectile dysfunction).
- erectile dysfunction ectile dysfunction
- suitable starting compounds can be provided in sufficient quantities. Because of the strict requirements regarding the purity of the drugs, they should be obtained with great purity. The reaction should also proceed in high yield to keep costs down and avoid waste disposal problems.
- the object of the invention is to provide a process for the preparation of compounds of the formula I which is simple to carry out and which provides the compound of the formula I in good yields and in high purity.
- R ⁇ stands for a linear or branched alkyl group with 1 to 6 carbon atoms, especially methyl, and a nitrile of the formula III
- R 1 has the meaning given above, are reacted in a solvent in solution or suspension in the presence of an acid.
- the radical R of the carboxylic acid ester of the formula II is preferably methyl, ethyl or propyl, further preferably isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, but also n-pentyl, neopentyl. Isopentyl or hexyl used.
- the alkylene radical is preferably, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl , 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl , 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-3-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, linear or branched heptyl, octyl, nonyl or decyl , Furthermore, R 1 can be but-2-en-yl or hex-3-en-yl.
- Cyclopentylmethylene, cyclohexylmethylene, cyclohexylethylene, cyclohexylpropylene or cyclohexylbutylene can be used as cycloalkyl or cycloalkylalkylene radicals having 5 to 12 carbon atoms.
- the cycloalkyl radicals preferably comprise 5 to 7 carbon atoms. Examples are cyclopentyl, cyclohexyl or cycloheptyl groups.
- R 1 can be a phenyl or a phenylmethyl radical.
- radicals mentioned are each simply substituted by -COOH, -COOA, -CONH 2 , -CONHA, - CON (A) 2 or -CN.
- A stands for alkyl with 1 to 6 carbon atoms. Examples of suitable groups are methyl, ethyl or propyl, and isopropyl, butyl, isobutyl, sec-butyl or tert-butyl as well as n-pentyl, neopentyl, isopentyl or hexyl.
- the compounds of the formula I are obtained as salts. These generally precipitate out of the reaction solution as a crystalline precipitate and can be obtained in sufficient purity by simple filtration.
- the synthesis of the compound of formula I is generally carried out in such a way that the carboxylic acid ester of formula II and the nitrile of formula III are placed in a suitable solvent and then the acid is added, for example by introducing it into the solution as a gas ,
- the yield of the reaction and the purity of the reaction product of the formula I can, however, be significantly increased and the reaction time considerably shortened if an excess of acid is first dissolved in the solvent, preferably the solvent is saturated with the acid, and then the 2-aminobenzothiophene 3-carboxylic acid esters of the formula II and the nitrile of the formula III are added.
- An excess of acid is understood to mean such a high amount of acid that with quantitative conversion of the compounds of the formula I and II and subsequent precipitation as a salt, unbound acid still remains in the solution. This amount of acid should already be present in the reaction mixture at the beginning of the reaction.
- the reaction can be carried out in such a way that first a, preferably saturated, solution of the acid in the solvent is prepared and, separately therefrom, a solution which contains the compounds of the formula I and the formula II.
- the two solutions can then either be poured into a reaction vessel for reaction at the same time, or the acid solution is introduced and the solution of the compounds of the formula I and the formula II is added.
- the acid solution should be added as quickly as possible to dissolve the compounds of the formula I and the formula II.
- the solvent is selected from the group formed by ethers, alcohols, esters, water, formamides, amines, carboxylic acids, chlorinated hydrocarbons and mixtures thereof.
- a particularly suitable solvent is dioxane.
- Suitable ethers are, for example, diethyl ether, diisopropyl ether. Tetrahydrofuran or dioxane.
- Suitable alcohols are, for example, methanol, ethanol, isopropanol. n-propanol, n-butanol or tert-butanol.
- Glycol ethers such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), diethylene glycol dimethyl ether (diglyme) are also suitable.
- Suitable amides are, for example, acetamide, dimethylacetamide, N-methylpyrrolidone or dimethylformamide.
- a suitable carboxylic acid is, for example, glacial acetic acid.
- ethyl acetate can be used as the ester.
- Suitable chlorinated hydrocarbons are, for example, trichlorethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane. Mixtures of the solvents mentioned can also be used.
- the acids are suitably selected from the group that is formed by
- Bronsted acids and Lewis acids especially hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, polyphosphoric acid, methanesulfonic acid, Trifluoromethanesulfonic acid, trifluoroacetic acid, aluminum trichloride and boron trifluoride.
- Gaseous acids, in particular hydrogen chloride, are particularly suitable.
- the reaction is suitably carried out at a temperature of -10 ° C to 100 ° C, preferably 0 ° C to 60 ° C, especially 10 ° C to 50 ° C.
- the compounds of the formula I represent a valuable starting material for further syntheses.
- a further activation of the compound of the formula I can be achieved if, in a further step, the compound of the formula I with a chlorinating agent into a compound of the formula IV
- the chlorine can easily be substituted by appropriate nucleophiles.
- the chlorinating agent is suitably selected from the group formed by SOCl 2 , POCl 3 , PCI 5 , C1COCOC1.
- the compounds of the formula II and III are either known or can be prepared by a person skilled in the art by known synthetic routes.
- An exemplary synthesis of the compounds of the formulas II and III is described below on the basis of particularly preferred compounds.
- the reactions can be carried out analogously for other radicals R 1 and R 2 .
- trans-4-cyanocyclohexanecarboxylic acid methyl ester starts from trans-cyclohexane-1,4-dicarboxylic acid methyl ester £, which is first saponified with KOH to form monomethyl ester 9. This is first converted into the acid chloride with thionyl chloride and then into the acid amide IQ with ammonia. The desired nitrile 11 is finally obtained from the acid amide IQ. H 3 COOC, HOOC, OH 1. SOCl 2
- compounds 2 and 11 are cyclized to give imidone 12.
- compound L2 By reaction with thionyl chloride, compound L2 can be obtained whose chlorine group can be substituted nucleophilically and is thus available as a starting compound for the synthesis of a large number of pharmacologically active substances.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00983247A EP1244675A1 (de) | 1999-12-07 | 2000-12-07 | Verfahren zur herstellung von thienopyrimidinen |
BR0016170-5A BR0016170A (pt) | 1999-12-07 | 2000-12-07 | Processo para preparação de tienopirimidinas |
MXPA02005084A MXPA02005084A (es) | 1999-12-07 | 2000-12-07 | Procedimiento para fabricar tienopirimidinas. |
KR1020027007019A KR20020053888A (ko) | 1999-12-07 | 2000-12-07 | 티에노피리미딘의 제조 방법 |
CA002392692A CA2392692A1 (en) | 1999-12-07 | 2000-12-07 | Process for preparing thienopyrimidines |
PL00355153A PL355153A1 (en) | 1999-12-07 | 2000-12-07 | Method for producing thienopyrimidines |
SK754-2002A SK7542002A3 (en) | 1999-12-07 | 2000-12-07 | Method for producing thienopyrimidines |
AU20064/01A AU2006401A (en) | 1999-12-07 | 2000-12-07 | Method for producing thienopyrimidines |
JP2001543546A JP2003516406A (ja) | 1999-12-07 | 2000-12-07 | チエノピリミジンの製造方法 |
US10/149,125 US6689885B2 (en) | 1999-12-07 | 2000-12-07 | Method for producing thienopyrimidines |
HU0203754A HUP0203754A2 (hu) | 1999-12-07 | 2000-12-07 | Eljárás tienopirimidinek előállítására |
NO20022671A NO20022671L (no) | 1999-12-07 | 2002-06-06 | Fremgangsmåte for fremstilling av tienopyrimidiner |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19958926A DE19958926A1 (de) | 1999-12-07 | 1999-12-07 | Verfahren zur Herstellung von Thienopyrimidinen |
DE19958926.7 | 1999-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001042248A1 true WO2001042248A1 (de) | 2001-06-14 |
Family
ID=7931692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/012351 WO2001042248A1 (de) | 1999-12-07 | 2000-12-07 | Verfahren zur herstellung von thienopyrimidinen |
Country Status (19)
Country | Link |
---|---|
US (1) | US6689885B2 (de) |
EP (1) | EP1244675A1 (de) |
JP (1) | JP2003516406A (de) |
KR (1) | KR20020053888A (de) |
CN (1) | CN1407988A (de) |
AR (1) | AR026731A1 (de) |
AU (1) | AU2006401A (de) |
BR (1) | BR0016170A (de) |
CA (1) | CA2392692A1 (de) |
CZ (1) | CZ20021847A3 (de) |
DE (1) | DE19958926A1 (de) |
HU (1) | HUP0203754A2 (de) |
MX (1) | MXPA02005084A (de) |
NO (1) | NO20022671L (de) |
PL (1) | PL355153A1 (de) |
RU (1) | RU2002118333A (de) |
SK (1) | SK7542002A3 (de) |
WO (1) | WO2001042248A1 (de) |
ZA (1) | ZA200203794B (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7274295B2 (en) * | 2002-10-30 | 2007-09-25 | At&T Bls Intellectual Property, Inc. | Instantaneous mobile access to all pertinent life events |
-
1999
- 1999-12-07 DE DE19958926A patent/DE19958926A1/de not_active Withdrawn
-
2000
- 2000-12-06 AR ARP000106452A patent/AR026731A1/es not_active Application Discontinuation
- 2000-12-07 CN CN00816708A patent/CN1407988A/zh active Pending
- 2000-12-07 CZ CZ20021847A patent/CZ20021847A3/cs unknown
- 2000-12-07 SK SK754-2002A patent/SK7542002A3/sk unknown
- 2000-12-07 KR KR1020027007019A patent/KR20020053888A/ko not_active Application Discontinuation
- 2000-12-07 AU AU20064/01A patent/AU2006401A/en not_active Abandoned
- 2000-12-07 WO PCT/EP2000/012351 patent/WO2001042248A1/de not_active Application Discontinuation
- 2000-12-07 JP JP2001543546A patent/JP2003516406A/ja active Pending
- 2000-12-07 EP EP00983247A patent/EP1244675A1/de not_active Withdrawn
- 2000-12-07 US US10/149,125 patent/US6689885B2/en not_active Expired - Fee Related
- 2000-12-07 HU HU0203754A patent/HUP0203754A2/hu unknown
- 2000-12-07 CA CA002392692A patent/CA2392692A1/en not_active Abandoned
- 2000-12-07 RU RU2002118333/04A patent/RU2002118333A/ru not_active Application Discontinuation
- 2000-12-07 BR BR0016170-5A patent/BR0016170A/pt not_active IP Right Cessation
- 2000-12-07 MX MXPA02005084A patent/MXPA02005084A/es unknown
- 2000-12-07 PL PL00355153A patent/PL355153A1/xx unknown
-
2002
- 2002-05-13 ZA ZA200203794A patent/ZA200203794B/en unknown
- 2002-06-06 NO NO20022671A patent/NO20022671L/no not_active Application Discontinuation
Non-Patent Citations (4)
Title |
---|
C. J. SHISHOO ET. AL.: "Reaction of Nitriles Under Acidic Conditions. Part III. A Facile Synthesis of Thienopyrimidin-4(3H)-ones.", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 21, no. 2, March 1984 (1984-03-01), pages 375 - 80, XP000983906 * |
C. J. SHISHOO ET. AL.: "Reaction of nitriles under acidic conditions. Part IV. Synthesis of some 2-substitued quinazolin-4-ones and thienopyrimidin-4-ones of biological interest and isolation of o-functionalized amidine intermediates.", INDIAN JOURNAL OF CHEMISTRY SECTION B.,, vol. 28B, no. 12, December 1989 (1989-12-01), pages 1039 - 47, XP000983872 * |
C. J. SHISHOO ET. AL.: "Studies on the Synthesis of 2-(2-ARylvinyl)thieno[2,3-d]pyrimidines.", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 22, no. 3, May 1985 (1985-05-01), pages 825 - 30, XP000983905 * |
K. G. DAVE ET. AL.: "Reaction of Nitriles under Acidic Conditions . Part I. A General Method of Synthesis of Condensed Pyrimidines.", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 17, 1980, pages 1497 - 1500, XP002059630 * |
Also Published As
Publication number | Publication date |
---|---|
ZA200203794B (en) | 2003-11-26 |
DE19958926A1 (de) | 2001-06-13 |
CN1407988A (zh) | 2003-04-02 |
PL355153A1 (en) | 2004-04-05 |
AR026731A1 (es) | 2003-02-26 |
EP1244675A1 (de) | 2002-10-02 |
JP2003516406A (ja) | 2003-05-13 |
US6689885B2 (en) | 2004-02-10 |
NO20022671D0 (no) | 2002-06-06 |
SK7542002A3 (en) | 2002-12-03 |
MXPA02005084A (es) | 2004-08-23 |
BR0016170A (pt) | 2002-08-20 |
US20030096994A1 (en) | 2003-05-22 |
CZ20021847A3 (cs) | 2002-10-16 |
AU2006401A (en) | 2001-06-18 |
NO20022671L (no) | 2002-06-06 |
RU2002118333A (ru) | 2003-12-20 |
CA2392692A1 (en) | 2001-06-14 |
KR20020053888A (ko) | 2002-07-05 |
HUP0203754A2 (hu) | 2003-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69530989T2 (de) | Neue pyrimidinderivate und verfahren zu ihrer herstellung | |
WO2006018220A2 (de) | Verfahren zur herstellung von dihydropteridinonen | |
DE602005004547T2 (de) | Pyrimidobenzimidazolderivate und verwendung damit als agonisten oder antagonisten von melanocortinrezeptoren | |
CH622261A5 (de) | ||
DE2255172A1 (de) | Imidazotriazinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneipraeparate | |
EP0789019B1 (de) | Verfahren zur Herstellung von 4-Oxoimidazoliniumsalzen | |
DE69710052T2 (de) | Verfahren zur herstellung von zwischenprodukten für pestizide | |
EP2099773B1 (de) | Neues verfahren zur herstellung von 4,4'-(1-methyl-1,2-ethandiyl)-bis-(2,6-piperazindion) | |
DE10337773A1 (de) | Kristallisation von festen Formen von Clopidogrel-Additionssalzen | |
DE68914471T2 (de) | Thieno[2,3-d]azepinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen. | |
DE60316047T2 (de) | Verfahren zur Herstellung von Olanzapine und ein Zwischenprodukt dafür | |
DE1695929C3 (de) | 1 ^-Dihydro-1 -hydroxy^-imino^-amino-6-methylpyrimidine sowie ein Verfahren zu deren Herstellung | |
DE2449030A1 (de) | Neue pyridin-derivate | |
WO2001042248A1 (de) | Verfahren zur herstellung von thienopyrimidinen | |
DE60116902T2 (de) | Neue desloratadinsalze, verfahren zu deren synthese und diese enthaltende pharmazeutische zusammensetzungen | |
DE2534962C3 (de) | cis-3,4-Ureylenthiophan-l,l-dioxid und Verfahren zu seiner Herstellung | |
DE2454619A1 (de) | Verfahren zur herstellung neuer heterocyclischer verbindungen | |
DE2841644C2 (de) | ||
DE2819873A1 (de) | N-phenyl-n-(4-piperidinyl)-amide, verfahren zu deren herstellung und deren verwendung als analgetika | |
DE60129699T2 (de) | Methoden zur darstellung von in 9-stellung substituierten hypoxanthinderivaten | |
DE69009765T2 (de) | Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
DE2653251A1 (de) | Azabicyclo eckige klammer auf 3.1.o eckige klammer zu hexan-derivate, ihre herstellung und verwendung | |
EP2313377B1 (de) | Verfahren zur stereoselektiven synthese bicyclischer heterocyclen | |
DE69310186T2 (de) | 1,2-dihydro-2-oxo-3-aminochinoxalin derivate, ihre verwendung als heilmittel | |
DE1470293C3 (de) | Substituierte 8-(4'-p-Fluorphenyl-4'-oxobutyl)-2,8- diazaspiro- eckige Klammer auf 4,5 eckige Klammer zu decan-1,3- dione und ihre Säureadditionssalze bzw. Verfahren zu deren Herstellung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002/03794 Country of ref document: ZA Ref document number: 200203794 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/005084 Country of ref document: MX Ref document number: IN/PCT/2002/692/KOL Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2392692 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2002-1847 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7542002 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027007019 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008167087 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20064/01 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2001 543546 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000983247 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200200611 Country of ref document: VN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027007019 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2002 2002118333 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2000983247 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2002-1847 Country of ref document: CZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10149125 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000983247 Country of ref document: EP |